- Tislelizumab is a novel anti-PD-1 monoclonal antibody approved by the NMPA, EMA, and FDA for widespread development for the treatment of advanced or metastatic esophageal squamous cell carcinoma and for the treatment of various types of cancer. , zanubrutinib is used to treat certain hematologic malignancies, with several studies supporting its favorable efficacy and safety profile.
- Under this strategic alliance, Glenmark will provide regional development, registration and commercialization responsibility for cancer patients around the world, providing access to Beigene's innovative oncology medicines. India.
mumbai, india, May 21, 2024 /PRNewswire/ — Glenmark Specialty SA (Glenmark), a subsidiary of Glenmark Pharmaceuticals Ltd, a global research-driven pharmaceutical company, today entered into an exclusive marketing and distribution agreement with BeiGene, a global oncology company. announced. Under the agreement, Glenmark plans to register and commercialize Beigene's oncology drugs tislelizumab and zanubrutinib in 2013. India.
Here's what he said about this partnership: Alok MalikPresident and Head of India Formulation, Glenmark Pharmaceuticals said: IndiaThe addition of tislelizumab and zanubrutinib to our oncology portfolio underscores our dedication to the cancer community and our commitment to providing access to novel therapies to the entire cancer community. India”
“this Our collaboration is a testament to our shared vision to enhance access to health care. Asia,” Said Adam Roach, Vice President and General Manager Asia Pacific At Beigene. ”We take great pride in advancing mission-driven access, especially given the serious burden of disease. IndiaRising cancer rates require comprehensive medical solutions, and this is a commitment we share with our partners at Glenmark,” Roach said.
The population exceeds 1.43 billion people, India It is the most populous country in the world and ranks as the largest lower-middle income country.1,2 This partnership is timely for many low- and middle-income countries, including: India, the burden of cancer is increasing. According to recent statistics, India It has the third highest number of cancer cases in the world, and it is predicted that by 2040, the number of cancer cases could reach 2.08 million, an increase of 57.5 percent from 2020.3 Currently, cancer claims approximately 900,000 lives each year. India.Four
Although solid tumors continue to make up the majority of cancers diagnosed, of particular concern is the rapidly increasing incidence of blood cancers. Blood cancer is the third highest in the world after the United States and the United States. China.Five in IndiaEvery year, a blood cancer diagnosis is made every five minutes, resulting in an estimated 70,000 deaths.Five In the midst of this harsh reality, Glenmark envisions a future where affordable and effective treatments are a beacon of hope for those in need.
About tislelizumab
Tislelizumab is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity for PD-1. It is designed to minimize binding to her Fc-gamma (Fcγ) receptors on macrophages, which help the body's immune cells detect and fight tumors.
About zanubrutinib
Zanubrutinib is a small molecule inhibitor of Bruton's tyrosine kinase (BTK) designed to completely and sustainably inhibit the BTK protein by optimizing bioavailability, half-life, and selectivity. Zanubrutinib has differentiated pharmacokinetics compared to other approved BTK inhibitors and has been demonstrated to inhibit the proliferation of malignant B cells in many disease-associated tissues.
About Glenmark Pharmaceuticals Co., Ltd.
Glenmark Pharmaceuticals Limited (BSE: 532296) | (NSE: GLENMARK) is a research-driven global pharmaceutical company with a presence across branded, generic and OTC segments. It focuses on the therapeutic areas of respiratory medicine, dermatology, and oncology. The company has 11 world-class manufacturing facilities on four continents and operates in more than 80 countries. In Vivo/Scrip 100, Glenmark ranks among the top 100 companies in the 2022 R&D and pharmaceutical sales rankings. Meanwhile, Generics Bulletin/In Vivo ranks it among the top 50 generic drug and biosimilar companies by sales in 2022. Glenmark's greenhouse gas (GHG) emissions reduction targets have been approved by the Science Based Target Initiative (SBTi) for 2023, which has given Glenmark his 2023 Greenhouse Gas (GHG) emission reduction targets approved by the Science Based Target Initiative (SBTi).second pharmaceutical company in India To achieve this. The organization has impacted the lives of approximately 3 million people over the past 10 years through its CSR activities. For more information, please visit www.glenmarkpharma.com. Follow us on LinkedIn (Glenmark Pharmaceuticals) and Instagram (glenmark_pharma).
About Beigene
BeiGene is a global oncology company discovering and developing innovative treatments that are more affordable and accessible for cancer patients around the world. We have a broad portfolio and are accelerating the development of a diverse pipeline of novel therapeutics through internal capabilities and collaboration. We are working to fundamentally improve access to medicines for even more patients who need them. Our global team of more than 10,000 colleagues spans five continents and continues to grow. To learn more about BeiGene, visit www.beigene.com and follow us on LinkedIn. X (formerly known as Twitter) and Facebook.
References:
- Statista. 20 most populous countries in 2024accessed https://www.statista.com/statistics/262879/countries-with-the-largest-population/ April 2024.
- Sharma G, Harbinder P, Challenges for low- and middle-income countries in achieving universal health care: An Indian perspective; 2023. Available from https://pubmed.ncbi.nlm.nih.gov/36655151/#:~:text=India%20is%20the%20largest%20lower,18%25%20of%20the%20world's%20population accessed April 2024.
- Ferley J, Arvik M, Lam F, et al. World Cancer Observatory: Cancer Today. Lyon, FranceIn: International Agency for Research on Cancer. 2020. Available from https://gco.iarc.fr/today/, accessed April 2024.
- Ferley J, Arvik M, Lamb F, Colombetto M, Merry L, Piñeros M, et al. World Cancer Observatory: Cancer Today. India fact sheet. lyon FranceIn: International Agency for Research on Cancer; 2022. Accessible from https://gco.iarc.who.int/media/globocan/factsheets/populations/356-india-fact-sheet.pdf April 2024.
- Chalby Multispecialty Hospital. Blood cancer – increasing burden on Indian societyhttps://www.shalby.org/blood-cancer-a-growing-burden-to-indian-;society/#:~:text=According%20to%20various%20sources%2C%20India,year%20 because% Accessed 20of%20blood%20cancer April 2024.
contact:
From Glenmark Pharmaceutical Co., Ltd.
Udaykumar Murthy
+91 9960377617
[email protected]
From Beijin
Louise Carter +61 474 231 049
[email protected]
Logo: https://mma.prnewswire.com/media/451507/PRNE_Glenmark_Logo.jpg
